List of nationally authorised medicinal products

Size: px
Start display at page:

Download "List of nationally authorised medicinal products"

Transcription

1 30 November 2017 EMA/806830/2017 Human Medicines Evaluation Division Active substance: piroxicam Procedure no.: PSUSA/ / Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.

2 FELDEN 10 mg Kapseln not available PFIZER CORPORATION AUSTRIA GESELLSCHAFT M.B.H. FELDEN 0,5% - Gel not available PFIZER CORPORATION AUSTRIA GESELLSCHAFT M.B.H. FELDEN 20 mg lösbare Tabletten not available PFIZER CORPORATION AUSTRIA GESELLSCHAFT M.B.H. FELDEN 20 mg Ampullen not available PFIZER CORPORATION AUSTRIA GESELLSCHAFT M.B.H. FELDEN Quick-Solve 20 mg Lyotabletten not available PFIZER CORPORATION AUSTRIA GESELLSCHAFT M.B.H. FELDEN 20 mg Kapseln not available PFIZER CORPORATION AT AUSTRIA GESELLSCHAFT M.B.H. Piroxicam EG 20 mg not available BE EUROGENERICS N.V./S.A. BE dispergeerbare tabletten Piroxicam EG 20 mg/ml not available BE EUROGENERICS N.V./S.A. BE oplossing voor injectie Piroxicam EG 20 mg not available BE EUROGENERICS N.V./S.A. BE Tabletten zur Herstellung einer Suspension zum Einnehmen Piroxicam EG 20 mg/ml not available BE EUROGENERICS N.V./S.A. BE Injektionslösung Piroxicam EG 20 mg not available BE EUROGENERICS N.V./S.A. BE comprimés dispersibles Piroxicam EG 20 mg not available BE EUROGENERICS N.V./S.A. BE capsules Piroxicam EG 20 mg/ml not available BE EUROGENERICS N.V./S.A. BE solution injectable Piroxicam EG 20 mg Kapseln not available BE EUROGENERICS N.V./S.A. BE Piroxicam EG 20 mg gélules not available BE EUROGENERICS N.V./S.A. BE where AT AT AT AT AT EMA/806830/2017 Page 2/13

3 Feldene 20 mg Hartkapseln not available BE PFIZER S.A. (BELGIUM) BE Feldene 10 mg Hartkapseln not available BE PFIZER S.A. (BELGIUM) BE Feldene 20 mg Zäpfchen not available BE PFIZER S.A. (BELGIUM) BE Feldene Lyotabs 20 mg not available BE PFIZER S.A. (BELGIUM) BE Schmelztabletten Feldene IM 20 mg/ml not available BE PFIZER S.A. (BELGIUM) BE Injektionslösung Feldene 0,5% Gel not available BE PFIZER S.A. (BELGIUM) BE Feldene Dispersal 20 mg not available BE PFIZER S.A. (BELGIUM) BE Tabletten zur Herstellung einer Suspension zum Einnehmen Feldene 20 mg suppositoires not available BE PFIZER S.A. (BELGIUM) BE Feldene 20 mg gélules not available BE PFIZER S.A. (BELGIUM) BE FELDENE 0,5 % gel not available BE PFIZER S.A. (BELGIUM) BE Feldene Lyotabs 20 mg not available BE PFIZER S.A. (BELGIUM) BE comprimés orodispersibles Feldene 10 mg gélules not available BE PFIZER S.A. (BELGIUM) BE Feldene Dispersal 20 mg not available BE PFIZER S.A. (BELGIUM) BE comprimés dispersibles Feldene IM 20 mg/ml not available BE PFIZER S.A. (BELGIUM) BE solution injectable Feldene 10 mg harde not available BE PFIZER S.A. (BELGIUM) BE capsules Feldene 20 mg harde not available BE PFIZER S.A. (BELGIUM) BE capsules Feldene Dispersal 20 mg not available BE PFIZER S.A. (BELGIUM) BE Dispergeerbare tabletten Feldene Lyotabs 20 mg not available BE PFIZER S.A. (BELGIUM) BE Orodispergeerbare tabletten FELDENE 0,5% gel not available BE PFIZER S.A. (BELGIUM) BE Feldene 20 mg zetpillen not available BE PFIZER S.A. (BELGIUM) BE Feldene IM 20 mg/ml oplossing voor injectie not available BE PFIZER S.A. (BELGIUM) BE where EMA/806830/2017 Page 3/13

4 BREXINE -DRYFIZ 20 mg BRAUSETABLETTEN (Brausetabletten) BREXINE-DRYFIZ 20 mg BRUISTABLETTEN BREXINE -DRYFIZ 20 mg COMPRIMÉS EFFERVESCENTS BREXINE 20 mg TABLETTEN not available BE CHIESI SA/NV BE not available BE CHIESI SA/NV BE not available BE CHIESI SA/NV BE not available BE CHIESI SA/NV BE BREXINE 20 mg TABLETTEN not available BE CHIESI SA/NV BE BREXINE 20 mg not available BE CHIESI SA/NV BE COMPRIMÉS????????? 20 mg???????? not available PROMEDICA S.R.L. BG FELDENE not available PFIZER HELLAS, A.E. CY FELDENE not available PFIZER HELLAS, A.E. CY FELDENE not available PFIZER HELLAS, A.E. CY BREXIN 20 mg tablets not available VARNAVAS HADJIPANAYIS CY LTD. (LATSIA) FLAMEXIN, TABLETY not available 29/116/96-C CHIESI FARMACEUTICI CZ Pirox-CT 20 mg Tabletten not available ABZ-PHARMA GMBH DE Piroxicam-ratiopharm 20 mg not available RATIOPHARM GMBH DE Injektionslösung Felden, gel not available PFIZER APS DK Felden, dispergible tabletter not available PFIZER APS DK FELDENE, 0,5% geel not available PFIZER EUROPE MA EEIG EE BREXIN, 20 mg suukaudse not available NORAMEDA UAB EE lahuse pulber BREXIN, 20 mg tabletid not available NORAMEDA UAB EE FELDENE 20 mg/ml, not available PFIZER, S.L. ES Solución inyectable FELDENE FLAS 20 mg, not available PFIZER, S.L. ES liofilizado oral FELDENE 10 mg, cápsulas duras not available PFIZER, S.L. ES where EMA/806830/2017 Page 4/13

5 FELDENE 20 mg, cápsulas duras FELDEGEL Piroxicam Gel al 0.5% Uso Cutáneo not available PFIZER, S.L. ES not available PFIZER, S.L. ES Salvacam 5 mg/g Gel not available LABORATORIOS SALVAT, ES S.A. SASULEN 5 mg/g gel not available LABORATORIOS VERIS, S.A. ES Felden 0,5 % gel not available PFIZER OY FI FELDEN 0,5 % geeli not available PFIZER OY FI BREXIN 20 mg, comprimé not available PIERRE FABRE MEDICAMENT sécable BREXIN 20 mg, comprimé not available SAS PIERRE FABRE effervescent MEDICAMENT BREXIN 20 mg, comprimé not available PIERRE FABRE MEDICAMENT sécable BREXIN 20 mg, comprimé not available SAS PIERRE FABRE effervescent MEDICAMENT BREXIN 20 mg, comprimé not available SAS PIERRE FABRE effervescent MEDICAMENT BREXIN 20 mg, comprimé not available SAS PIERRE FABRE effervescent MEDICAMENT FELDENE DISPERSIBLE 20 not available PFIZER HOLDING ANCE mg, comprimé sécable FELDENE DISPERSIBLE 20 not available PFIZER HOLDING ANCE mg, comprimé sécable FELDENE DISPERSIBLE 20 not available PFIZER HOLDING ANCE mg, comprimé sécable FELDENE 20 mg/1 ml, not available PFIZER HOLDING ANCE solution injectable en ampoule (IM) FELDENE 20 mg, gélule not available PFIZER HOLDING ANCE FELDENE DISPERSIBLE 20 mg, comprimé sécable not available PFIZER HOLDING ANCE where EMA/806830/2017 Page 5/13

6 FELDENE 20 mg/1 ml, solution injectable en ampoule (IM) not available PFIZER HOLDING ANCE FELDENE 10 mg, gélule not available PFIZER HOLDING ANCE FELDENE 20 mg, gélule not available PFIZER HOLDING ANCE GELDENE 0,5 POUR CENT, not available PFIZER HOLDING ANCE gel pour application locale GELDENE 0,5 POUR CENT, not available PFIZER HOLDING ANCE gel pour application locale FELDENE 20 mg, not available PFIZER HOLDING ANCE suppositoire FELDENE 20 mg, not available PFIZER HOLDING ANCE suppositoire not available CHIESI S.A.S. comprimé effervescent not available CHIESI S.A.S. comprimé sécable not available CHIESI S.A.S. comprimé sécable not available CHIESI S.A.S. comprimé sécable not available CHIESI S.A.S. comprimé sécable not available CHIESI S.A.S. comprimé effervescent not available CHIESI S.A.S. comprimé effervescent not available CHIESI S.A.S. comprimé effervescent FELDENE 0,5% (w/w) γέλη not available 41098/10/ PFIZER HELLAS, A.E. GR Feldene 10 mg not available 41095/10/ PFIZER HELLAS, A.E. GR διασπειρόμενα δισκία Feldene 20 mg διασπειρόμενα δισκία not available 41097/10/ PFIZER HELLAS, A.E. GR where EMA/806830/2017 Page 6/13

7 BREXIN Dref 20 mg, αναβράζοντα δισκία BREXIN 20 mg, κοκκία μιας δόσης για πόσιμο υγρό σε φακελίσκους not available 5247/ CHIESI HELLAS A.E.B.E. GR not available 21244/91/ CHIESI HELLAS A.E.B.E. GR BREXIN 20 mg, δισκία not available 20011/91/ CHIESI HELLAS A.E.B.E. GR Feldene Dispersal 20 mg not available OGYI-T-1141/05 PFIZER KFT. HU diszpergálódó tabletta Feldene Dispersal 20 mg not available OGYI-T-1141/07 PFIZER KFT. HU diszpergálódó tabletta Feldene kemény kapszula not available OGYI-T-1141/02 PFIZER KFT. HU Feldene kemény kapszula not available OGYI-T-1141/01 PFIZER KFT. HU Feldene Dispersal 20 mg not available OGYI-T-1141/06 PFIZER KFT. HU diszpergálódó tabletta Feldene Dispersal 20 mg not available OGYI-T-1141/08 PFIZER KFT. HU diszpergálódó tabletta Brexin 20 mg pezsgőtabletta not available OGYI-T-8393/05 CHIESI PHARMACEUTICALS HU GMBH Brexin 20 mg pezsgőtabletta not available OGYI-T-8393/07 CHIESI PHARMACEUTICALS HU GMBH Brexin 20 mg pezsgőtabletta not available OGYI-T-8393/08 CHIESI PHARMACEUTICALS HU GMBH Brexin 20 mg tabletta not available OGYI-T-8393/03 CHIESI PHARMACEUTICALS HU GMBH Feldene 20 mg capsules, not available PA 19/24/3 PFIZER LIMITED IE hard Feldene 10 mg capsules, not available PA 19/24/2 PFIZER LIMITED IE hard Feldene 5 mg/g Gel not available PA 19/24/8 PFIZER LIMITED IE Felden 20 mg dreifitöflur not available PFIZER APS IS Felden 0,5% hlaup not available PFIZER APS IS SINARTROL 30 mg not available SPA SOCIETÀ PRODOTTI IT compresse ANTIBIOTICI SINARTROL INFIAMMAZIONE E DOLORE 1,5% crema not available SPA SOCIETÀ PRODOTTI ANTIBIOTICI IT where EMA/806830/2017 Page 7/13

8 SINARTROL 1,5% crema not available SPA SOCIETÀ PRODOTTI IT ANTIBIOTICI PIROFTAL not available BRUSCHETTINI S.R.L IT FELDENE 20 mg compresse not available PFIZER ITALIA S.R.L. IT solubili FELDENE Fast 20 mg not available PFIZER ITALIA S.R.L. IT compresse sublinguali FELDENE 20 mg capsule not available PFIZER ITALIA S.R.L. IT rigide FELDENE 20 mg/1 ml not available PFIZER ITALIA S.R.L. IT soluzione iniettabile per uso intramuscolare FELDENE Fast 20 mg not available PFIZER ITALIA S.R.L. IT compresse sublinguali FELDENE 20 mg supposte not available PFIZER ITALIA S.R.L. IT FELDENE CREMADOL 1% not available PFIZER ITALIA S.R.L. IT crema PIROFTAL not available BRUSCHETTINI S.R.L IT BREXIN 20 mg compresse not available PROMEDICA S.R.L. IT CICLADOL 20 mg compresse not available MASTER PHARMA S.R.L. IT CICLADOL 20 mg compresse not available MASTER PHARMA S.R.L. IT CICLADOL 20 mg compresse not available MASTER PHARMA S.R.L. IT CICLADOL 20 mg compresse not available MASTER PHARMA S.R.L. IT CICLADOL 20 mg compresse not available MASTER PHARMA S.R.L. IT CICLADOL 20 mg compresse not available MASTER PHARMA S.R.L. IT CICLADOL 20 mg compresse not available MASTER PHARMA S.R.L. IT CICLADOL 20 mg granulato not available MASTER PHARMA S.R.L. IT per soluzione orale BREXIN 20 mg compresse not available PROMEDICA S.R.L. IT where EMA/806830/2017 Page 8/13

9 BREXIN 20 mg compresse BREXIN 20 mg granulato per soluzione orale BREXIVEL 20 mg/1 ml Soluzione iniettabile per uso intramuscolare not available PROMEDICA S.R.L. IT not available PROMEDICA S.R.L. IT not available PROMEDICA S.R.L. IT BREXIN 20 mg compresse not available PROMEDICA S.R.L. IT BREXIN 20 mg compresse not available PROMEDICA S.R.L. IT BREXIN 20 mg supposte not available PROMEDICA S.R.L. IT CICLADOL 20 mg supposte not available MASTER PHARMA S.R.L. IT LENOTAC 14 mg cerotto not available I.B.N. SAVIO S.R.L. IT medicato LENOTAC 14 mg cerotto not available I.B.N. SAVIO S.R.L. IT medicato LENOSPREAD CREMA not available I.B.N. SAVIO S.R.L. IT ANTIFLOG 1% Gel not available FABBRICA ITALIANA IT RITROVATI MEDICINALI ED AFFINI F.I.R.M.A. - SCANNING 14 mg cerotto not available IBSA FARMACEUTICI ITALIA IT medicato SCANNING 14 mg cerotto not available IBSA FARMACEUTICI ITALIA IT medicato PIROFTAL not available BRUSCHETTINI S.R.L IT CLEVIAN 1% GEL not available AESCULAPIUS IT FARMACEUTICI S.R.L. LENOSPREAD CREMA not available I.B.N. SAVIO S.R.L. IT Brexin 20 mg tabletės not available LT/1/2000/1566/001 NORAMEDA UAB LT Brexin 20 mg milteliai not available LT/1/2000/1566/002 NORAMEDA UAB LT geriamajam tirpalui Piroxicam EG 20 mg not available EUROGENERICS N.V./S.A. LU comprimés dispersibles Piroxicam EG 20 mg/ml not available EUROGENERICS N.V./S.A. LU solution injectable Piroxicam EG 20 mg gélules not available EUROGENERICS N.V./S.A. LU where EMA/806830/2017 Page 9/13

10 Feldene Dispersal 20 mg Tabletten zur Herstellung einer Suspension zum Einnehmen not available PFIZER S.A. (BELGIUM) LU Feldene 20 mg Zäpfchen not available PFIZER S.A. (BELGIUM) LU Feldene IM 20 mg/ml not available PFIZER S.A. (BELGIUM) LU Injektionslösung Feldene 0,5% Gel not available PFIZER S.A. (BELGIUM) LU Feldene Lyotabs 20 mg not available PFIZER S.A. (BELGIUM) LU Schmelztabletten Feldene 20 mg Hartkapseln not available PFIZER S.A. (BELGIUM) LU Feldene 10 mg Hartkapseln not available PFIZER S.A. (BELGIUM) LU FELDENE 0,5 % gel not available PFIZER S.A. (BELGIUM) LU Feldene 20 mg suppositoires not available PFIZER S.A. (BELGIUM) LU Feldene Dispersal 20 mg not available PFIZER S.A. (BELGIUM) LU comprimés dispersibles Feldene Lyotabs 20 mg not available PFIZER S.A. (BELGIUM) LU comprimés orodispersibles Feldene 10 mg Gélules not available PFIZER S.A. (BELGIUM) LU Feldene 20 mg Gélules not available PFIZER S.A. (BELGIUM) LU Feldene IM 20 mg/ml not available PFIZER S.A. (BELGIUM) LU solution injectable BREXINE 20 mg not available 0430/ CHIESI SA/NV LU COMPRIMÉS BREXIN 20 mg tabletes not available NORAMEDA UAB LV BREXIN 20 mg pulveris not available NORAMEDA UAB LV iekškigi lietojama škiduma pagatavošanai Brexidol 20 mg tabletter not available 8013 CHIESI FARMACEUTICI NO FELDENE, roztwór do not available R/2346 PFIZER EUROPE MA EEIG PL wstrzykiwań, 20 mg/ml Flamexin, 191,2 mg, tabletki not available 9222 CHIESI PHARMACEUTICALS PL GMBH Flexar 20 mg/1 ml solução injectável not available A. MENARINI PORTUGAL, FARMACÊUTICA, S.A. where EMA/806830/2017 Page 10/13

11 Feldene 20 mg comprimidos Feldene 20 mg comprimidos Feldene 20 mg comprimidos Feldene 20 mg comprimidos Feldene 20 mg comprimidos Feldene 20 mg/1 ml solução injectável not available LABORATÓRIOS PFIZER, not available LABORATÓRIOS PFIZER, not available LABORATÓRIOS PFIZER, not available LABORATÓRIOS PFIZER, not available LABORATÓRIOS PFIZER, not available LABORATÓRIOS PFIZER, Feldene 20 mg cápsulas not available LABORATÓRIOS PFIZER, Feldene 20 mg comprimidos not available LABORATÓRIOS PFIZER, Feldene 20 mg/1 ml solução not available LABORATÓRIOS PFIZER, injectável Feldene 20 mg comprimidos not available LABORATÓRIOS PFIZER, Feldene 20 mg comprimidos not available LABORATÓRIOS PFIZER, Feldene 20 mg comprimidos not available LABORATÓRIOS PFIZER, Feldene 20 mg comprimidos not available LABORATÓRIOS PFIZER, Feldene 20 mg cápsulas not available LABORATÓRIOS PFIZER, Feldene 5 mg/g gel not available LABORATÓRIOS PFIZER, Feldene 20 mg supositórios not available LABORATÓRIOS PFIZER, BREXIN 20 mg comprimidos not available CHIESI FARMACEUTICI BREXIN 20 mg comprimidos not available CHIESI FARMACEUTICI where EMA/806830/2017 Page 11/13

12 BREXIN 20 mg granulado not available CHIESI FARMACEUTICI BREXIN 20 mg granulado not available CHIESI FARMACEUTICI BREXIN 20 mg granulado not available CHIESI FARMACEUTICI BREXIN 20 mg comprimidos not available CHIESI FARMACEUTICI efervescentes BREXIN 20 mg comprimidos not available CHIESI FARMACEUTICI efervescentes Flexar 5 mg/g gel not available A. MENARINI PORTUGAL, FARMACÊUTICA, S.A. Flexar 20 mg supositórios not available A. MENARINI PORTUGAL, FARMACÊUTICA, S.A. Flexar 20 mg cápsulas not available A. MENARINI PORTUGAL, FARMACÊUTICA, S.A. Flexar 20 mg cápsulas not available A. MENARINI PORTUGAL, FARMACÊUTICA, S.A. Bruxicam 0,5%, picături not available 455/2007/01 BRUSCHETTINI S.R.L RO oftalmice, soluţie Bruxicam 0,5%, picături not available 455/2007/01 BRUSCHETTINI S.R.L RO oftalmice, soluţie Flamexin, comprimate not available 7147/2006/01 CHIESI FARMACEUTICI RO efervescente, 20 mg Flamexin, comprimate not available 7147/2006/02 CHIESI FARMACEUTICI RO efervescente, 20 mg Flamexin, comprimate not available 7147/2006/03 CHIESI FARMACEUTICI RO efervescente, 20 mg Flamexin, 20 mg, pulbere not available 7597/2006/01 CHIESI FARMACEUTICI RO pentru soluţie orală Flamexin, 20 mg, pulbere not available 7597/2006/02 CHIESI FARMACEUTICI RO pentru soluţie orală Flamexin, 20 mg, pulbere not available 7597/2006/03 CHIESI FARMACEUTICI RO pentru soluţie orală Flamexin, 20 mg, pulbere pentru soluţie orală not available 7597/2006/04 CHIESI FARMACEUTICI RO where EMA/806830/2017 Page 12/13

13 Flamexin, 20 mg, pulbere pentru soluţie orală Flamexin, 20 mg, pulbere pentru soluţie orală Flamexin, 20 mg, comprimate Flamexin, 20 mg, comprimate Flamexin, 20 mg, comprimate Bruxicam 0,5%, picături oftalmice, soluţie not available 7597/2006/05 CHIESI FARMACEUTICI RO not available 7597/2006/06 CHIESI FARMACEUTICI RO not available 7146/2006/01 CHIESI FARMACEUTICI RO not available 7146/2006/02 CHIESI FARMACEUTICI RO not available 7146/2006/03 CHIESI FARMACEUTICI RO not available 455/2007/01 BRUSCHETTINI S.R.L RO Brexidol 20 mg tabletter not available CHIESI FARMACEUTICI SE Flamexin 20 mg granulát not available 29/0115/99-S CHIESI FARMACEUTICI SK Flamexin 20 mg tablety not available 29/0114/99-S CHIESI FARMACEUTICI SK Piroxicam 0.5% Gel not available PL AUDEN MCKENZIE (PHARMA UK DIVISION) LTD Piroxicam Manx 0.5% w/w not available PL 14251/0028 MANX HEALTHCARE LTD UK Gel FELDENE 20mg CAPSULES not available PL 00057/0146 PFIZER LIMITED UK Feldene Melt 20mg not available PL 00057/0352 PFIZER LIMITED UK FELDENE 10mg CAPSULES not available PL 00057/0145 PFIZER LIMITED UK FELDENE GEL not available PL 00057/0284 PFIZER LIMITED UK Piroxicam Capsules 10mg not available PL 20416/0137 CRESCENT PHARMA UK LIMITED Piroxicam Capsules 20mg not available PL 20416/0138 CRESCENT PHARMA UK LIMITED Piroxicam 0.5% w/w Gel - PL40378/0179 TORRENT PHARMA LTD. UK where EMA/806830/2017 Page 13/13

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 September 2017 EMA/658556/2017 Procedure Management and Committees Support Active substance: loratadine Procedure no.: PSU/00001907/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 17 May 2018 EMA/303456/2018 Human Medicines Evaluation Division Active substance: bromazepam Procedure no.: PSUSA/00000435/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/817337/2017 Human Medicines Evaluation Division Active substance: Itraconazole Procedure no.: PSUSA/00001798/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/608492/2018 Human Medicines Evaluation Division Active substance: betahistine Procedure no.: PSUSA/00000389/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 06 July 2017 EMA/436040/2017 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00001815/201610 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/231137/2018 Human Medicines Evaluation Division Active substance: fluvoxamine Procedure no.: PSUSA/00001458/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/615391/2018 Human Medicines Evaluation Division Active substance: tobramycin (nebuliser solution) (apart from centrally authorised product) Procedure no.: PSUSA/00009316/201712 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/619619/2018 Human Medicines Evaluation Division Active substance: haemophilus influenzae / klebsiella ozaenae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 21 June 2017 EMA/610895/2017 Human Medicines Evaluation Division Active substance: felbamate Procedure no.: PSUSA/00010155/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/677092/2015 Procedure Management and Committees Support Active substance: glatiramer Procedure no.: PSUSA/00001529/201411 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/795271/2017 Human Medicines Evaluation Division Active substance: vinorelbine Procedure no.: PSUSA/00003124/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 November 2018 EMA/880324/2018 Human Medicines Evaluation Division Active substance: enalapril Procedure no.: PSUSA/00001211/201803 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 08 March 2018 EMA/170163/2018 Human Medicines Evaluation Division Active substance: enalapril / hydrochlorothiazide Procedure no.: PSUSA/00001212/201707 30 Churchill Place Canary Wharf London E14 5EU United

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/612853/2015 Procedure Management and Committees Support Active substance: tobramycin (nebuliser solution) Procedure no.: PSUSA/00009316/201412 30 Churchill Place Canary Wharf London

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 26 October 2017 EMA/690754/2017 Human Medicines Evaluation Division Active substance: fish oil / olive oil / soybean oil / triglycerides mediumchain Procedure no.: PSUSA/00010223/201702 30 Churchill Place

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 20 July 2016 EMA/270645/2015 Procedure Management and Committees Support Active substance: apomorphine Procedure no.: PSUSA/00000227/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 09 June 2017 EMA/36849/2017 Human Medicines Evaluation Division Active substance(s): brimonidine / timolol Procedure No.: PSUSA/00000431/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 January 2018 EMA/24585/2018 Human Medicines Evaluation Division Active substance: esomeprazole / naproxen Procedure no.: PSUSA/00001270/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/817351/2017 Human Medicines Evaluation Division Active substance: Lidocaine / prilocaine (not centrally authorised product) Procedure no.: PSUSA/00001867/201703 30 Churchill Place

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/639167/2017 Human Medicines Evaluation Division Active substance: zanamivir Procedure no.: PSUSA/00003141/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 13 September 2017 EMA/706786/2017 Human Medicines Evaluation Division Active substance: Octenidine dihydrochloride / phenoxyethanol Procedure no.: PSUSA/00002199/201701 30 Churchill Place Canary Wharf

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 May 2017 EMA/288255/2017 Human Medicines Evaluation Division Active substance: pilocarpine (ophthalmic formulation) Procedure no.: PSUSA/00002410/201608 30 Churchill Place Canary Wharf London E14 5EU

More information

Please note that this draft Annex I will be updated to amend information on concerned products/mahs

Please note that this draft Annex I will be updated to amend information on concerned products/mahs 22 March 2018 EMA/197481/2018 Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of, applicants, marketing authorisation holders in the member states for for omega-3

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/223740/2018 Human Medicines Evaluation Division Active substance: fludarabine Procedure no.: PSUSA/00001406/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 September 2017 EMA/604559/2017 Human Medicines Evaluation Division Active substance: iron / parenteral preparations Procedure no.: PSUSA/00010236/201701 30 Churchill Place Canary Wharf London E14 5EU

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 October 2017 EMA/784453/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): ipratropium / salbutamol Procedure No.: PSUSA/00001781/201701 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 September 2017 EMA/580096/2017 Human Medicines Evaluation Division Active substance: terbutaline Procedure no.: PSUSA/00002897/201612 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/812360/2017 Human Medicines Evaluation Division Active substance(s): mupirocin Procedure No.: PSUSA/00002096/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182668/2018 Human Medicines Evaluation Division Active substance(s): triamcinolone (topical and nasal formulations) Procedure No.: PSUSA/00003017/201707 30 Churchill Place Canary Wharf

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 July 2018 EMA/497430/2018 Human Medicines Evaluation Division Active substance: tafluprost / timolol Procedure no.: PSUSA/00010324/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/622830/2015 Procedure Management and Committees Support Active substance: azelastine Procedure no.: PSUSA/00000277/201412 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 14 April 2016 EMA/284169/2016 Procedure Management and Committees Support Active substance: influenza vaccine (split virion, inactivated) (non centrally products) Procedure no.: PSUSA/00010298/201508 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 October 2017 EMA/691535/2017 Human Medicines Evaluation Division Active substance: Haemophilus type b conjugate vaccines Procedure no.: PSUSA/00001584/201702 30 Churchill Place Canary Wharf London E14

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/658449/2017 Human Medicines Evaluation Division Active substance: olodaterol Procedure no.: PSUSA/00010245/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 July 2018 EMA/462856/2018 Human Medicines Evaluation Division Active substance: econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide Procedure no.: PSUSA/00001195/201711

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 24 January 2018 EMA/270645/2015 Human Medicines Evaluation Division Active substance: azithromycin (systemic use formulations) Procedure no.: PSUSA/00010491/201704 30 Churchill Place Canary Wharf London

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 21 February 2018 EMA/208334/2018 Human Medicines Evaluation Division Active substance: ibuprofen / pseudoephedrine Procedure no.: PSUSA/00001711/201707 30 Churchill Place Canary Wharf London E14 5EU United

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use

(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Austria Austria Bulgaria Bulgaria

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/227889/2018 Human Medicines Evaluation Division Active substance(s): typhoid polysaccharide vaccine Procedure No.: PSUSA/00003065/201708 30 Churchill Place Canary Wharf London E14 5EU

More information

(Invented) Name Strength Pharmaceutical form. Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml. 2.5 mg prolonged-release capsule, hard

(Invented) Name Strength Pharmaceutical form. Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml. 2.5 mg prolonged-release capsule, hard Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation holder(s) in the member states 1 Boehringer Ingelheim RCV GmbH & Co KG, Dr.

More information

(Invented) Name Strength Pharmaceutical form. Ergotop 10 mg - Tabletten. Ergotop 20 mg - Filmtabletten. Ergotop 30 mg - Filmtabletten

(Invented) Name Strength Pharmaceutical form. Ergotop 10 mg - Tabletten. Ergotop 20 mg - Filmtabletten. Ergotop 30 mg - Filmtabletten Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation holder(s) in the member states 1 Bulgaria Bulgaria Czech Republic Kwizda Pharma

More information

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008 European Medicines Agency Doc. Ref. EMEA/357907/2008 P/53/2008 EUROPEAN MEDICINES AGENCY DECISION of 20 July 2008 on the application for agreement of a Paediatric Investigation Plan for Atorvastatin calcium

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182904/2018 Human Medicines Evaluation Division Active substance(s): fluticasone propionate / formoterol fumarate dihydrate Procedure No.: PSUSA/00010339/201707 30 Churchill Place Canary

More information

European Medicines Agency decision

European Medicines Agency decision EMA/788583/2016 European Medicines Agency decision P/0363/2016 of 21 December 2016 on the agreement of a paediatric investigation plan and on the granting of a waiver for dipalmitoylphosphatidylcholine

More information

European Medicines Agency decision

European Medicines Agency decision EMA/574564/2017 European Medicines Agency decision P/0278/2017 of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Japanese encephalitis vaccine (inactivated,

More information

4,0 g/0,5 g. 2g/250 mg. 4 g/500 mg. 4g/0,5g 2.25 G/VIAL. injection 4.5 G/VIAL. injection. injection

4,0 g/0,5 g. 2g/250 mg. 4 g/500 mg. 4g/0,5g 2.25 G/VIAL. injection 4.5 G/VIAL. injection. injection ANNEX I List of the names, pharmaceutical forms, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Route of ) Austria Bulgaria Cyprus Cyprus Czech Republic

More information

Implementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO

Implementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO Implementation Report on the patient safety Recommendation 2009/C 151/01 Healthcare Systems Unit DG SANCO Published 15 November 2012 REPORT FROM THE COMMISSION TO THE COUNCIL on the basis of Member States'

More information

European Medicines Agency decision

European Medicines Agency decision EMA/75416/2018 European Medicines Agency decision P/0042/2018 of 16 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for dasatinib (Sprycel), (EMEA-000567-PIP01-09-M05)

More information

Annex I. Article 107i of Directive 2001/83/EC. Procedure number: EMEA/H/A-107i/ March 2013 EMA/147828/2013 Patient Health Protection

Annex I. Article 107i of Directive 2001/83/EC. Procedure number: EMEA/H/A-107i/ March 2013 EMA/147828/2013 Patient Health Protection 07 March 2013 EMA/147828/2013 Patient Health Protection Annex I List of the names, pharmaceutical s, strengths of the medicinal products, routes of, marketing authorisation holders in the member states

More information

European Medicines Agency decision

European Medicines Agency decision EMA/761887/2015 European Medicines Agency decision P/0307/2015 of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for odanacatib (EMEA- 001123-PIP01-11-M03)

More information

VARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014

VARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014 Rose-Marie Molina EMA Infoday London, 14th March 2014 Before 1234/2008 Regulation, variation procedures in the European Union for industry was synonymous of: - Lack of visibility about timelines - Lack

More information

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Prof. Ing. Juraj Nemec, CSc. Masaryk University, Czech Republic, Size of government

More information

Initial (Full) Marketing Authorisation application accelerated assessment timetables

Initial (Full) Marketing Authorisation application accelerated assessment timetables 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European

More information

European Medicines Agency decision

European Medicines Agency decision EMA/497687/2017 European Medicines Agency decision P/0245/2017 of 4 September 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for

More information

European Medicines Agency decision

European Medicines Agency decision EMA/654883/2017 European Medicines Agency decision P/0312/2017 of 30 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for cabotegravir (EMEA- 001418-PIP01-13-M01)

More information

European Union herbal monograph on Pistacia lentiscus L., resin (mastix)

European Union herbal monograph on Pistacia lentiscus L., resin (mastix) 7 July 2015 EMA/HMPC/46758/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pistacia lentiscus L., resin (mastix) Draft Discussion in Working Party on European Union

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 November 2017 EMA/845743/2017 Human Medicines Evaluation Division Active substance: ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus) Procedure no.: PSUSA/00010345/201702 30 Churchill

More information

Update on public hearing

Update on public hearing Update on public hearing PCWP/HCPWP joint meeting Presented by Juan Garcia Burgos on 0 September 017 Head of Public Engagement Department An agency of the European Union A public hearing provides An opportunity

More information

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Interested parties (organisations or individuals) that commented on the draft document as released for consultation. 25 January 2018 EMA/CHMP/729976/2017 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Paracetamol oral use, immediate release formulations product-specific bioequivalence

More information

European Medicines Agency decision

European Medicines Agency decision EMA/434825/2017 European Medicines Agency decision P/0235/2017 of 9 August 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for venetoclax (Venclyxto), (EMEA-002018-PIP02-16)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/605276/2014 European Medicines Agency decision P/0282/2014 of 28 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for lenvatinib (EMEA- 001119-PIP02-12-M02)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/848760/2017 European Medicines Agency decision P/0033/2018 of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M10)

More information

Ensuring protection of public health and patients in member states: priorities, constraints, opportunities

Ensuring protection of public health and patients in member states: priorities, constraints, opportunities Ensuring protection of public health and patients in member states: priorities, constraints, opportunities Dr. Christa Wirthumer-Hoche AGES Austrian Medicines and Medical Devices Agency Vienna, Austria

More information

European Union herbal monograph on Eschscholzia californica Cham., herba

European Union herbal monograph on Eschscholzia californica Cham., herba 28 January 2015 EMA/HMPC/680372/2013 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Eschscholzia californica Cham., herba Final Discussion in Working Party on European

More information

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Interested parties (organisations or individuals) that commented on the draft document as released for consultation. 31 May 2018 EMA/CHMP/258276/2017 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Dabigatran etexilate, hard capsules, 75 mg, 110 mg and 150 mg productspecific bioequivalence

More information

Draft Agreed by Pharmacokinetics Working Party February Adoption by CHMP for release for consultation 1 April 2016

Draft Agreed by Pharmacokinetics Working Party February Adoption by CHMP for release for consultation 1 April 2016 15 December 2016 Committee for Medicinal Products for Human Use (CHMP) Everolimus tablets 0.25 mg, 0.5 mg, 0.75 mg and 1 mg; 2.5 mg, 5 mg and 10 mg, dispersible tablets 0.1 mg and 0.25 mg; 2 mg, 3 mg and

More information

EUROPEAN CITIZENS DIGITAL HEALTH LITERACY

EUROPEAN CITIZENS DIGITAL HEALTH LITERACY Flash Eurobarometer 404 EUROPEAN CITIZENS DIGITAL HEALTH LITERACY SUMMARY Fieldwork: September 2014 Publication: November 2014 This survey has been requested by the European Commission, Directorate-General

More information

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11

More information

European Medicines Agency decision

European Medicines Agency decision EMA/757980/2016 European Medicines Agency decision P/0313/2016 of 21 December 2016 on the agreement of a paediatric investigation plan for complex of povidone and iodine / dexamethasone (SHP640) (EMEA-001936-PIP01-16)

More information

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11

More information

PUBLIC STATEMENT ON TROVAN / TROVAN IV / TURVEL / TURVEL IV (Trovafloxacin/Alatrofloxacin)

PUBLIC STATEMENT ON TROVAN / TROVAN IV / TURVEL / TURVEL IV (Trovafloxacin/Alatrofloxacin) The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 15 June 1999 EMEA/18046/99 PUBLIC STATEMENT ON TROVAN / TROVAN IV / TURVEL / TURVEL IV (Trovafloxacin/Alatrofloxacin)

More information

Trends in injecting drug use in Europe

Trends in injecting drug use in Europe Trends in injecting drug use in Europe Linda Montanari, Bruno Guarita and Danica Thanki Annual Expert Meeting on Drug-Related Infectious Diseases Lisbon, 15-17 October Overview of the presentation 1) Information

More information

European Medicines Agency decision

European Medicines Agency decision EMA/741983/2016 European Medicines Agency decision P/0324/2016 of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta), (EMEA-000498-PIP01-08-M06)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/137097/2017 European Medicines Agency decision P/0073/2017 of 17 March 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for

More information

European Medicines Agency decision

European Medicines Agency decision EMA/757977/2016 European Medicines Agency decision P/0364/2016 of 21 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for KEOC liquid extract ethanolic 30 per

More information

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on 11/01/2019 PL

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on 11/01/2019 PL Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected

More information

European Union herbal monograph on Peumus boldus Molina, folium

European Union herbal monograph on Peumus boldus Molina, folium 22 November 2016 EMA/HMPC/453725/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Peumus boldus Molina, folium Final Initial assessment Discussion in Working Party

More information

European Medicines Agency decision

European Medicines Agency decision EMA/155875/2015 European Medicines Agency decision P/0062/2015 of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M09)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/357972/2017 European Medicines Agency decision P/0173/2017 of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for colistimethate sodium (Colobreathe), (EMEA-000176-PIP01-07-M05)

More information

European Union herbal monograph on Ruscus aculeatus L. rhizoma

European Union herbal monograph on Ruscus aculeatus L. rhizoma 30 January 2018 EMA/188804/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Ruscus aculeatus L. rhizoma Draft Initial assessment Discussion in Working Party on European

More information

European Medicines Agency decision

European Medicines Agency decision EMA/208387/2017 European Medicines Agency decision P/0089/2017 of 6 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for melatonin (Circadin), (EMEA-000440-PIP02-11-M05)

More information

European Union herbal monograph on Glycine max (L.) Merr., lecithinum

European Union herbal monograph on Glycine max (L.) Merr., lecithinum 31 January 2017 EMA/HMPC/220599/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Glycine max (L.) Merr., lecithinum Final Discussion in Working Party on European Union

More information

European Medicines Agency decision

European Medicines Agency decision EMA/43935/2015 European Medicines Agency decision P/0015/2015 of 30 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for eslicarbazepine (acetate) (Zebinix) (EMEA-000696-PIP02-10-M05

More information

Decentralised Procedure. RMS Day 210 Assessment Report OVERVIEW. Budenofalk 9 mg gastro-resistant granules (Budesonide) UK/H/2778/001/DC

Decentralised Procedure. RMS Day 210 Assessment Report OVERVIEW. Budenofalk 9 mg gastro-resistant granules (Budesonide) UK/H/2778/001/DC Decentralised Procedure RMS Day 210 Assessment Report OVERVIEW Budenofalk 9 mg gastro-resistant granules (Budesonide) UK/H/2778/001/DC Applicant: Dr. Falk Pharma GmbH Reference Member State UK Start of

More information

European Medicines Agency decision

European Medicines Agency decision EMA/501874/2008 European Medicines Agency decision P/0303/2016 of 4 November 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for

More information

European Medicines Agency decision

European Medicines Agency decision EMA/348027/2017 European Medicines Agency decision P/0166/2017 of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for aciclovir (Sitavig and associated names),

More information

European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix

European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix 05 June 2018 EMA/HMPC/444244/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium Final Initial assessment Discussion in Working

More information

European Medicines Agency decision

European Medicines Agency decision EMA/776083/2014 European Medicines Agency decision P/0001/2015 of 7 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta) (EMEA-000498-PIP01-08-M04)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/281879/2015 European Medicines Agency decision P/0097/2015 of 8 May 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human

More information

European Medicines Agency decision

European Medicines Agency decision EMA/731087/2017 European Medicines Agency decision P/0341/2017 of 16 November 2017 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin

More information